SN
|
Study
|
Study Type
|
Study Place and Duration
|
Population
|
Intervention
|
Concomitant treatment
|
Outcome
|
1
|
Cao 2020 [45]
|
Retrospective Case series
|
China
January 3 – February 1, 2020
|
102
T:- 51
C:- 51
|
51 patients received corticosteroid therapy
|
Antiviral, antibiotics, Chinese medicine and immunoglobulin therapy along with respiratory support
|
At the end of the study
ICU
T=11/51 C=7/51
Non-ICU
T=40/51 C=44/51
|
2
|
Chen Q 2020 [21]
|
Retrospective observational study
|
China
January 1 – March 11, 2020
|
145
T:- 47
C:- 98
|
47 patients received corticosteroid therapy
|
Antiviral, Chinese medicine, Antibacterial, Immunoglobulin therapy
|
At the end of the study
Severely Ill
T:- 38/47 C:- 5/98
Non severely Ill:-
T:- 9/47 C:- 93/98
|
3
|
Chen TL 2020 [22]
|
Retrospective study
|
China
January 1 – February 20,2020
|
203
T:-107
C:- 96
Age < 65:- 148
Age > 65:- 55
T:- 34
C: 21
|
107 patients received corticosteroid
34 patients received in Age > 65
|
Antiviral, Immunoglobulin and respiratory support
|
At the end of study
Death
Age > 65:- 19
Age < 65:- 7
Among Age> 65
Death
T :- 14/34 C:- 5/21
Survival
T:- 20/34 C:- 16/21
|
4
|
Chen Xu 2020 [46]
|
Observational study
|
China
January 23- February 14,2020
|
T:- 67
C:- 224
|
67 patients received corticosteroid
|
Antiviral, Chinese medicine, Chloroquine and respiratory support
|
At the end of study
Death:- 2
Discharge :- 159
Hospitalized :- 130
Mild cases
T:- 13/67 C:- 16/224
Moderate cases
T:- 46/67 C:- 166/224
Severe cases:-
T:- 8/67 C:- 42/224
|
5
|
Chrobozcek 2020 [23]
|
Retrospective study
|
France
10 March-9 April 2020
|
70
T:- 21
C:- 49
|
32 patients received corticosteroid
|
Hydroxychloroquine, Azithromycin and Lopinavir
|
At the end of study
Non intubated
T:- 18/21 C:- 17/49
Intubated
T:- 3/21 C:- 32/49
|
6
|
Confalonieri 2020 [24]
|
Prospective Cohort
|
Italy
23 March – May 20, 2020
|
173
T:- 83
C:- 90
|
Standard of care plus Methylprednisolone (MP) 80 mg/kg IV bolus, followed by MP infusion of 80 mg/day in 240 mL normal saline at 10 mL/h for eight days and until achieving either a PaO2:FiO2 > 350 mmHg or a CRP < 20 mg/L
Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to < 20% of normal range and/or PaO2:FiO2 > 400 or SatHbO2 ≥ 95%.
|
Empiric antibiotics and respiratory support.
|
Admission to ICU, Need for invasive ventilation and Death by day 28
Mortality
T:- 6/83
C:- 21/90
ICU admission
T:- 15/83
C:- 27/90
Invasive ventilation
T:- 15/83
C:- 26/90
|
7
|
Cruz 2020 [25]
|
Retrospective cohort study
|
Spain
March 2020
|
463
T:- 396
C:- 67
|
Patients received 1 mg/kg/day methylprednisolone or equivalent, and steroid pulse in the treatment group
|
Hydroxychloroquine, Azithromycin, Antivirals, Immunomodulators and respiratory support
|
At the end of study
ARDS
T:- 240/396 C:- 58/67
Mortality:-
T:- 55/396 C:- 16/67
|
8
|
Feng 2020 [26]
|
Retrospective study
|
China
January 1 – February 15, 2020
|
476
T:- 127
C:- 349
|
Patients received corticosteroids in the treatment group.
|
Antiviral, antibiotics and antifungal
|
At the end of study
Discharge: - 403
Death: - 38
Remained in hospital: - 23
Lost to follow up: - 12
Outcomes in critical patients (T=52/127, C=18/349)
Discharge
T= 13/52; C= 10/18
Death T=21/52; C= 8/18
Remained in hospital T=13/52; C= 0/18
Among 3 CAT
Moderate
T:47/127 C=305/349
Severe
T:28/127 C=26/349
Critical
T:52/127, C=18/349
Severe+ critical T=80/127 C=44/349
|
9
|
Gong 2020 [27]
|
Retrospective comparison study
|
China
30 January – 20 February 2020
|
34
T: - 18
C: - 16
|
Patients received methylprednisolone in the treatment group
|
Antivirals and respiratory support
|
20 days after methylprednisolone
Complete absorption in 2
Partial absorption in 14 cases
Enlargement of lesion in 2 cases
Nucleic acid negative period T=29.11 ± 6.61 C=24.44 ± 5.21
|
10
|
Guan 2020 [28]
|
Retrospective study
|
China
11 December – 29 January 2020
|
1099
T: - 204
C: - 895
|
Patients received systemic glucorticoid in the treatment group
|
Antibiotics, antivirals, antifungal and respiratory support
|
At the end of study Disease Severity Nonsevere (N=926); T=127/204 C=799/895
Severe (N=173) T=77/204, C=96/895
Presence of Composite Primary End Point (admitted to the ICU, invasive mechanical ventilation, and death)= deterioration
Yes (N=67)
T=35 /204 C=32/895
No (N=1032) T=169/204 C=863/895
|
11
|
Hong Y 2020 [29]
|
Retrospective study
|
China
January – February 20, 2020
|
75
T: - 17
C: - 58
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotics, corticosteroid and respiratory support
|
Prolonged length of stay
T: - 9/17 C: - 16/58
Non prolonged length of stay
T: - 8/17 C: - 42/58
|
12
|
Hong KS 2020 [30]
|
Retrospective study
|
Korea
March 2020
|
98
T: - 18
C: - 80
|
Patients received corticosteroid in the treatment group
|
Antiviral, antibiotic, hydroxychloroquine and respiratory support
|
At the end of study
ICU
T: - 10/18 C: - 3/80
Non ICU
T: - 8/18 C: - 77/80
|
13
|
Hou 2020 [31]
|
Retrospective cohort study
|
China
21 January – 9 March 2020
|
101
T: - 32
C: - 69
;
|
Patients received corticosteroid in the treatment group
|
Antiviral, hydroxychloroquine and respiratory support
|
Improvement
T: - 18/32 C: - 66/69
Progression
T: - 14/32 C: - 3/69
|
14
|
Hu 2020 [32]
|
Retrospective study
|
China
8 January – February 20 2020
|
323
T: - 196/323
C: - 127/323
|
Patients received corticosteroid in treatment group
|
Antiviral, antibiotic and respiratory support
|
At the end of study
Favorable
T: - 142/196 C: - 118/127
Unfavorable
T: - 54/196 C: - 9/127
Non-severe
T: - 87/196 C: - 64/127
Severe
T: - 86/196 C: - 60/127
Critical
T: - 23/196 C: - 3/127
Critical +severe=172 T=109/196
C=63/127
|
15
|
Huang C 2020[12]
|
Prospective cohort study
|
China
December – January 2020
|
41
T: - 9
C: - 32
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic and respiratory support
|
At the end of the study
ICU
T: - 6/9 C: -7/32
Non ICU
T: -3/9 C: - 25/32
Hospitalized
T: - 0/9 C: - 7/32
Discharge
T: - 5/9 C: - 23/32
Death
T: - 4/9 C: - 2/32
ARDS
T: - 6/9 C: - 6/32
|
16
|
Huang M 2020 [33]
|
Retrospective cohort study
|
China
January 24 – February 23 2020
|
60 severe cases
Among severe cases
T: -34
C:- 26
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotics, Antifungal, interferon and respiratory support
|
At the end of the study
Improvement
T: - 27/34 C: - 25/26
Deterioration
T: - 7/34 C: - 1/26
|
17
|
Jiang 2020 [34]
|
Retrospective observational study
|
China
January 31 – February 16, 2020
|
60
T: - 9
C: - 51
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotics, Interferon, and respiratory support
|
At the end of study Non-severe
T=1/9 C=51/51 Severe
T=8/9 C=0/51
|
18
|
Lei 2020 [35]
|
Retrospective study
|
China
January 1 – February 5, 2020
|
34
T: - 16
C: - 18
|
Patients received corticosteroid in the treatment group
|
Antiviral, antibiotics, immunoglobulin and respiratory support
|
At the end of the study
ICU
T: - 9/16 C: - 6/18
Non ICU
T: - 7/16 C: - 12/18
|
19
|
Li 2020 [36]
|
Ambispective cohort study
|
China
January 26 – February 5, 2020
|
548
T: - 341
C: - 207
|
Patients received corticosteroid in the treatment group
|
Antiviral, immunoglobulin, vasopressor, and respiratory support
|
At the end of the study
Non-severe
T: - 145/341 C: - 134/207
Severe
T: - 196/341 C: - 73/207
|
20
|
Ling 2020 [7]
|
Retrospective study
|
China
January 20 – February 10, 2020
|
66
T: - 5
C: - 61
|
Patients received corticosteroid in treatment group
|
Not mentioned
|
Negative RT-PCR median (IQR)
T=15d (9.8-16.8)
C=8d(6-11)
|
21
|
Liu T 2020 [37]
|
Retrospective Study
|
China
January 21 – February 16 2020
|
80
T=29
C=51
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic, Antifungal, and respiratory support
|
Severe Cases: T=29/29 C=40/51
Non-Severe Cases:
T=0/29 C=11/51
Recovery=47 (Non-severe=10; Severe =37)
Hospitalization 33 (Non-severe=1; Severe =32)
|
22
|
Liu Y 2020 [38]
|
Retrospective Study
|
China
January 2 – February 1 2020
|
109
T=72
C=37
|
Glucocorticoid Therapy
|
Antiviral, Antibiotic, Immunoglobulin and respiratory support
|
Non ARDS:
T= 35/72 C=21/37
ARDS:
T=37/72 C=16/37
Death(31) : ARDS=26 Non ARDS=5
|
23
|
Lo IL 2020 [47]
|
Case series
|
China
January 21- February 16 2020
|
10
T=3
C=7
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic, Interferon and Respiratory support
|
Severe:
T= 3/3 C=1/7
Non-Severe:
T=0/3 C=6/7
|
24
|
Lu Xiaofan 2020 [11]
|
Retrospective Cohort Study
|
China
January 25- February 25 2020
|
244
T=151
C=93
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotics and Immunoglobulin
|
ARDS:
T=81/151 C=6/93
MV:
T=78/151 C=4/93
Mortality: T=79/151 C=5/93
Subgroup Mortality:
T=12/31 C=5/31
|
25
|
Sun L 2020 [39]
|
Retrospective Observational Study
|
China
January 20- February 15 2020
|
55
T=25
C=30
|
Patients received corticosteroid in the treatment group
|
Antiviral, interferon, Antibiotic and respiratory support
|
Severe:
T=11/25 C=4/30
Non severe:
T =14/25 C=26/30
Hospitalized: T=19/25 C=7/30
Discharged: T=6/25 C=23/30
|
26
|
Wan S 2020 [48]
|
Case Series
|
China
January 23- February 8 2020
|
135
T=36
C=99
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic, Oxygen Support, Traditional Chinese Medicine and respiratory support
|
Severe:
T=21/36 C= 19/99
Non-Severe Cases T= 15/36 C=80/99
Hospitalization 120
Discharge 15
Death 1
|
27
|
Wang D 2020 [49]
|
Retrospective Case Series
|
China
January 1-28 2020
|
138
T=62
C=76
|
Patients received corticosteroid in the treatment group
|
Antiviral and respiratory support
|
ICU
T=26/62 C=10/76
Non-ICU
T=36/62 C=66/76
|
28
|
Wang D2 2020 [13]
|
Retrospective Case Series
|
China
December 2019 - February 2020
|
107
T= 62
C=45
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic and respiratory support
|
survivors(S): 88
Non-survivors (NS):19
S: T= 44/62 C= 44/45
NS:T=18/62 C=1/45
|
29
|
Wang Z 2020 [15]
|
Case Series
|
China
January 19- 19 2020
|
67
T=10
C=57
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic, Antifungal, and Arbidol
|
Hospitalization: T=3/10 C=41/57
DeathT=4/10 C=1/57
Discharged T=3/10 C=15/57
|
30
|
Wang K 2020 [14]
|
Ambispective Observational Cohort Study
|
China
|
T= 548
|
Patients received corticosteroid in the treatment group
|
Antiviral including Arbidol
|
At the end of the study, D15;
Survivors (n=470), T=276/341, C=194/207
Non-survivors (n=78); T=65/341, C=13/207
|
31
|
Wu C 2020 [9]
|
Retrospective Cohort Study
|
China
December 25 2019 - January 26 2020
|
201
T=62
C=139
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic, Oxygen Therapy, Immunomodulators, and Antioxidant
|
ARDS =84
Death among ARDS = 44/84
T=23/50 C=21/34
Discharged = 27/50 C= 13/34
|
32
|
Wu J 2020 [16]
|
Retrospective Cohort Study
|
China
December 26 2019- March 15 2020
|
1763
Severe= 1514
T=531 C=983
Critical=249
T=159 C=90
|
Patients received corticosteroid in the treatment group
|
|
Severe cases
Hospital stay: T=15.2d C=11.5d
Progression to critical case: T=149/531 C=104/983
Death: T=83/531 C=26/983
Critical Cases: Hospital stay, d : T=12.9 C=15.6
Death: T=70/159 C=14/90
|
33
|
Xu Y 2020 [50]
|
Retrospective Multicenter Case Series
|
China
February 7-28 2020
|
69
T=6
C=63
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic
|
Severe Cases:
T= 6/6 C=19/63
Non-severe Cases: T=0/6 C=44/63
|
34
|
Xu Yonghao 2020 [40]
|
Multi Centered Retrospective Observational Cohort Study
|
China
|
45
T=21
C=24
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic, Antifungal, Convalescent plasma, and Albumin
|
Intubation T=10/21 C=10/24
Non- Intubated T=11/21 C= 14/24
|
35
|
Yang L 2020 [41]
|
Retrospective Study
|
China
January 30- February 8 2020
|
200
T=112
C=88
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic
|
ICU: T=20/112 C=9/88
Non-ICU: T=92/112 C=79/88
Hospitalization:143
Discharge:42
Death:15
|
36
|
Yang X 2020 [42]
|
Single centered Retrospective Observational Study
|
China
Late December- January 26 2020
|
52
T=30
C=22
|
Patients received corticosteroids in the treatment group.
|
Antiviral, Oxygen Therapy, Antibacterial, Immunoglobulin
|
Survivors: T=14/30 C=6/22
Non Survivors: T=16/30 C=16/22
ARDS: 35
MV:37
|
37
|
Yu H 2020 [17]
|
Retrospective Cohort
|
China
January – March 2020
|
775
T: - 238
C: - 537
|
Patients received corticosteroid in treatment group
|
Antivirals and respiratory support
|
Overall
Mortality Rate
T: -44/238
C: - 18/537
Recovery
T: - 161/238
C: - 433/537 Undetectable viral RNA (Clearance) T: - 83/238
C: - 311/537
Duration of hospital stay days T: - 18.7±12.0
C: - 15.0±8.9
Duration of viral RNA (Clearance) days
T: - 11.9±9.2
C: - 9.4±8.3
Mild-Moderate
T=117/238 C=437/537
Severe to critical
T=121/238 C=100/537
|
38
|
Zha L 2020 [43]
|
Observational Study
|
China January 24- February 24 2020
|
31
T=11
C=20
|
Patients received corticosteroids in the treatment group.
|
Antiviral, Antibiotic
|
Viral Clearance (days) median: T=15 C=14
Hospital stay (days) median: T=20 C=17
Recovered: T=11/11 C=15/20
|
39
|
Zhang G 2020 [51]
|
Retrospective Case Series
|
China
January 2- February 10 2020
|
221
T=115
C=106
|
Patients received corticosteroids in the treatment group.
|
Antiviral
|
Non-severe Cases: T=75/115 C=91/106
Severe Cases: T=40/115 C=15/106
Hospitalization (167)
Severe=36, Non-severe=131
Discharge (42) Severe=7, Non-severe=35
Death (12) Severe=12
|
40
|
Zhao X 2020 [44]
|
Retrospective Study
|
China
January 16- February 10 2020
|
91
T=79
C=12
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibiotic
|
Non severe: T=54/79 C=7/12
Severe: T=25/79 C=5/12
|
41
|
Zhou F 2020 [18]
|
Multi-centered Retrospective Cohort Study
|
China
December 29 2019 - January 31 2020
|
191
T=57
C=134
|
Patients received corticosteroid in the treatment group
|
Antiviral, Antibacterial, Oxygen Therapy, Immunoglobulin
|
Discharged:137
Died:54
Survivors:
T=31/57 C=106/134
Non Survivors: T=26/57
C=28/134
|